3320:HKEXChina Resources Pharmaceutical Group Ltd. Analysis

China Resources Pharmaceutical is trading at HK$4.59, barely above its 20‑day (HK$4.57) and 50‑day (HK$4.56) simple moving averages but well below the 200‑day SMA of HK$4.91, indicating a short‑term price bounce with long‑term downside pressure. Technical indicators are mixed: the RSI sits at 53, the MACD line has turned bullish (histogram +0.001), and volume is increasing, suggesting modest buying interest near the support level of HK$4.34. Fundamentally, the stock appears deeply undervalued – a trailing P/E of 9 versus an industry average of 26.7, a price‑to‑book of 0.51 and a dividend yield of 2.98% with a modest payout ratio of ~30%. The DCF model values the company at roughly HK$26.30, implying a potential upside of over 40%, while forward earnings suggest a PE of 6.7. However, the balance sheet shows a high debt‑to‑equity ratio of 74% and negative free cash flow, though operating cash flow remains positive, and ROE is only 7.6%, highlighting execution risk. The company faces medium regulatory risk in China’s pharmaceutical sector, moderate geographic concentration, and low beta (near zero) but elevated 30‑day volatility of ~20%.